Bosh sahifaRLF • SWX
add
RELIEF THERAPEUTICS Holding SA
Yopilish kursi
4,13 CHF
Kunlik diapazon
4,15 CHF - 7,24 CHF
Yillik diapazon
1,06 CHF - 7,24 CHF
Bozor kapitalizatsiyasi
89,30 mln CHF
Oʻrtacha hajm
123,06 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
SWX
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (CHF) | iyn, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 2,83 mln | 87,03% |
Joriy xarajat | 4,04 mln | -41,31% |
Sof foyda | -2,28 mln | 91,93% |
Sof foyda marjasi | -80,60 | 95,69% |
Har bir ulushga tushum | — | — |
EBITDA | -1,27 mln | 74,88% |
Amaldagi soliq stavkasi | -14,01% | — |
Balans
Jami aktivlari
Jami passivlari
| (CHF) | iyn, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 10,73 mln | -16,20% |
Jami aktivlari | 70,92 mln | -43,61% |
Jami passivlari | 21,65 mln | -31,07% |
Umumiy kapital | 49,27 mln | — |
Tarqatilgan aksiyalar | 12,55 mln | — |
Narxi/balansdagi bahosi | 1,05 | — |
Aktivlardan daromad | -7,01% | — |
Kapitaldan daromad | -9,62% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (CHF) | iyn, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -2,28 mln | 91,93% |
Operatsiyalardan naqd pul | -1,58 mln | 69,75% |
Sarmoyadan naqd pul | -3,50 ming | 96,82% |
Moliyadan naqd pul | -308,00 ming | -114,76% |
Naqd pulning sof oʻzgarishi | -1,91 mln | 40,61% |
Boʻsh pul | -635,56 ming | 75,84% |
Haqida
Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. The company was incorporated as Relief Therapeutics Holdings AG and listed on the SIX Swiss Exchange in 2016. Wikipedia
Tashkil etilgan
2013
Xodimlar soni
36
